Eric Van Cutsem, MD, discusses a subgroup analysis involving patients 75 years of age and older in the Consign study of regorafenib for treatment-refractory metastatic colorectal cancer. The analysis found no major differences in safety compared with younger patients as long as the patients were fit enough to be eligible for treatment—so age itself is no reason to withhold regorafenib.
More than 3,000 cases reported in continental U.S.
Lumacaftor/ivacaftor combination previously approved for patients 12 years of age and older
“Artificial pancreas” adjusts insulin levels
Treatment reduces monthly migraine days
Organisms shed essential cell-wall molecules
Singleplex trumps Trioplex, lab chief says
Arm patch provides continuous glucose monitoring
Compound could be used in new anti-inflammatory agents
Approval decision scheduled for July
First stakeholder meeting to be held this month
P&T September 2016
Table of Contents
Regorafenib Safe for Older Colorectal Cancer Patients
ESMO World Congress on Gastrointestinal Cancer, June 29–July 2, 2016